Jove
Visualize
Contact Us

Related Experiment Videos

Plasminogen activator inhibitor-1 levels and polymorphisms.

Charles W Francis1

  • 1Vascular Medicine Unit, University of Rochester School of Medicine & Dentistry, Rochester, NY 14642, USA. charles_francis@urmc.rocheser.edu

Archives of Pathology & Laboratory Medicine
|November 8, 2002
PubMed
Summary

The link between plasminogen activator inhibitor-1 (PAI-1) levels or its 4G/5G gene variant and venous thromboembolism risk is unclear. Current evidence is conflicting, and PAI-1 testing is not recommended for thrombophilia evaluation.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Thrombotic complications in patients with cancer: Advances in pathogenesis, prevention, and treatment-A report from ICTHIC 2021.

Research and practice in thrombosis and haemostasis·2022
Same author

Vascular Imaging in the Asymptomatic High-risk Cancer Population: A Role for Thrombosis Screening and Therapy Management.

Journal of ultrasound in medicine : official journal of the American Institute of Ultrasound in Medicine·2021
Same author

American Society of Hematology 2019 guidelines for management of venous thromboembolism: prevention of venous thromboembolism in surgical hospitalized patients.

Blood advances·2019
Same author

Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer: ASCO Clinical Practice Guideline Update.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2019
Same author

PGM Guidelines for Description of Criteria and Methods for Testing of Specificity of Assay Methods for Quantities in the Fibrinolytic System.

EJIFCC·2019
Same author

Approach to pancytopenia: Diagnostic algorithm for clinical hematologists.

Blood reviews·2018
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Area of Science:

  • Biochemistry
  • Genetics
  • Hematology

Background:

  • Plasminogen activator inhibitor-1 (PAI-1) is a key regulator of the fibrinolytic system.
  • Elevated PAI-1 levels may theoretically increase thrombosis risk by inhibiting fibrinolysis.
  • The 4G/5G polymorphism in the PAI-1 gene promoter influences its expression levels.

Purpose of the Study:

  • To review existing literature on the association between PAI-1 and venous thromboembolic disease (VTE).
  • To evaluate the evidence linking PAI-1 plasma levels and the PAI-1 4G/5G polymorphism to VTE risk.

Main Methods:

  • Comprehensive review of published medical literature.
  • Utilized computerized databases and secondary sources for evidence identification.

Related Experiment Videos

Main Results:

  • Early studies suggested a link between PAI-1 levels and VTE, but were limited by methodological issues (e.g., circadian variation, acute phase response).
  • Studies on the PAI-1 4G/5G polymorphism have yielded inconsistent results regarding VTE risk.
  • Some research indicates higher PAI-1 plasma levels in individuals with the 4G/4G genotype.

Conclusions:

  • Conflicting evidence exists regarding the association between PAI-1 levels/genotype and VTE risk.
  • Insufficient data currently supports the routine use of PAI-1 levels or genotype for thrombophilia assessment.